Rare Biomarkers Specimen Collection and Stabilization Market Updates : Projected to Surpass USD 54.2 Billion by 2031

The global rare biomarkers specimen collection and stabilization market is expected to reach $54.2 billion by 2031, CAGR of 8.7% from 2022 to 2031.

WILMINGTON, DELAWARE , UNITED STATES, April 22, 2024 /EINPresswire.com/ -- Allied Market Research published a report, titled, "Rare Biomarkers Specimen Collection and Stabilization Market by Type (Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes Vesicles), by Product (Isolation Kits and Reagent, Blood Collection Tubes, Systems), by Application (Oncology, Cardiovascular Diseases, NIPT, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031." According to the report, the global rare biomarkers specimen collection and stabilization industry generated $23.3 billion in 2021, and is expected to reach $54.2 billion by 2031, witnessing a CAGR of 8.7% from 2022 to 2031.

Biomarkers serve as crucial measures in clinical assessments, aiding in monitoring and predicting health states for individuals or populations, thereby guiding appropriate therapeutic interventions. These markers span various biological systems such as cardiovascular, metabolic, and immune systems. They range from easily measurable indicators like blood pressure and cholesterol levels to body measurements like BMI and waist-to-hip ratio.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐑𝐞𝐩𝐨𝐫𝐭 https://www.alliedmarketresearch.com/request-sample/A13226

In the realm of disease management, biomarkers play a pivotal role in cancer detection, screening, diagnosis, treatment, and monitoring. Unlike traditional cancer drugs that targeted both cancerous and healthy cells, newer therapies are more targeted, aiming to eliminate cancer cells while preserving healthy ones.

Market growth in rare biomarker specimen collection and stabilization is primarily driven by factors such as increasing cancer and chronic disease prevalence, a growing elderly population, heightened adoption of advanced healthcare services, and enhanced R&D investments by biopharmaceutical companies. For instance, in conditions like Hereditary Angioedema (HAE), personalized treatment based on biomarker status can significantly enhance therapeutic management.

Despite these growth drivers, challenges like high development costs and a shortage of skilled personnel hinder market expansion. Nonetheless, emerging economies like India, China, Mexico, and Brazil offer new opportunities, especially in pharmacogenomics and disease diagnosis.

The rare biomarkers specimen collection and stabilization market is segmented based on types like circulating cell-free DNA, circulating tumor cells, and exosome vesicles. In 2021, circulating cell-free DNA dominated the market due to its utility in detecting chromosomal anomalies in fetuses and as a promising tumor biomarker for cancer diagnosis and personalized medication guidance.

Product-wise, isolation kits & reagents witnessed substantial growth in 2021 and are expected to lead in the forecast period, driven by rising cancer and rare genetic disorder prevalence.

In terms of application, oncology saw significant growth in 2021 and is projected to lead, buoyed by increasing cancer cases and advancements in personalized medication.

Geographically, North America held the majority market share in 2021 and is likely to maintain dominance due to its high adoption of advanced imaging systems, increased healthcare expenditure, and presence of major key players. Meanwhile, the Asia-Pacific region is expected to register the fastest growth, fueled by demand for minimally invasive therapies, healthcare reforms, high population density, and prevalence of chronic diseases, particularly in countries like India and China.

𝐒𝐩𝐞𝐚𝐤 𝐭𝐨 𝐎𝐮𝐫 𝐀𝐧𝐚𝐥𝐲𝐬𝐭- https://www.alliedmarketresearch.com/connect-to-analyst/A13226

𝐋𝐞𝐚𝐝𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 𝐏𝐥𝐚𝐲𝐞𝐫𝐬
Agilent Technologies
Bio-Rad Laboratories, Inc.
Charles River Laboratories Inc.
F. Hoffman La Roche AG
Merck KGaA
Miltenyi Biotec
Perkin Elmer
Qiagen
Thermofisher Scientific, Inc.
Siemens AG

𝐊𝐞𝐲 𝐟𝐢𝐧𝐝𝐢𝐧𝐠𝐬 𝐨𝐟 𝐭𝐡𝐞 𝐬𝐭𝐮𝐝𝐲
By type, the circulating cell free DNA segment was the highest contributor to the market in 2021.
By product, the isolation kits & reagents segment was the highest contributor in 2021.
By application, the oncology dominated the market in 2021 and is expected to continue this trend during the forecast period.
By region, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

𝐊𝐞𝐲 𝐁𝐞𝐧𝐞𝐟𝐢𝐭𝐬 𝐅𝐨𝐫 𝐒𝐭𝐚𝐤𝐞𝐡𝐨𝐥𝐝𝐞𝐫𝐬
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the rare biomarkers specimen collection and stabilization market analysis from 2021 to 2031 to identify the prevailing rare biomarkers specimen collection and stabilization market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the rare biomarkers specimen collection and stabilization market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global rare biomarkers specimen collection and stabilization market trends, key players, market segments, application areas, and market growth strategies.

David Correa
Allied Market Research
+1 5038946022
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn